Document is current

Article History

Received: 1 July 2021

Accepted: 12 November 2022

First Online: 7 December 2022

Declarations

:

: The Regional Ethical Committee of North Jutland, Denmark, has approved the trial protocol (N-20200068). If any modifications of the original trial protocol are deemed necessary, a supplemental protocol will be submitted to the Regional Ethical Committee of North Jutland for approval. If the Regional Ethical Committee of North Jutland determines that any modification of the original protocol require that participants are informed about the modification, the participants will be contacted by telephone.

: No identifiable details about the individual participant will be published. The authors do not expect that any future studies using the data from the trial will require further consent from the participants. Should further informed consent be needed, contrary to expectation, the participants will be contacted by mail.

: The principal investigator declares no conflict of interest. Several authors are former or present employees at Novo Nordisk A/S and hold shares at Novo Nordisk A/S.